- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prevention of venous thromboembolism Chronic stable atherosclerotic disease
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 530KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 123KB)
Rivaroxaban – November 2024
Rivaroxaban Tablet 2.5 mg, Tablet 10 mg; Xarelto®
Last updated
30 May 2025